Clinical Trial Update: SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SBRT with nivolumab/ipilimumab in metastatic/Stage IV kidney cancer has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Kidney Cancer Metastatic
• Renal Cell Carcinoma

Drugs mentioned

• SBRT (stereotactic body radiotherapy)
• nivolumab/ipilimumab

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Kidney Cancer Metastatic, Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-03-30